Skip to main content
Year archive

Purple Biotech Ltd. — 2023 filings

All 81 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2023, sourced directly from the official regulator.

81 Filings
2023 Period
2023 filings (81)
Filing Released Lang
Appoints Dr. Yael Margolin to its Board of Directors
Board/Management Information
2023-12-20 English
Appoints Dr. Yael Margolin to its Board of Directors
Board/Management Information
2023-12-20 English
6K:Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
Regulatory Filings
2023-12-14 English
6K:Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
Report Publication Announcement
2023-12-14 English
6K-Corporate Presentation November 2023
Investor Presentation
2023-11-21 English
6K-Corporate Presentation November 2023
Report Publication Announcement
2023-11-21 English
Reports Third Quarter 2023 Financial Results
Interim / Quarterly Report Q3 2023
2023-11-21 English
Reports Third Quarter 2023 Financial Results
Report Publication Announcement 9M 2023
2023-11-21 English
PROSPECTUS
Investor Presentation
2023-11-14 English
PROSPECTUS
Capital/Financing Update
2023-11-14 English
FORM F-1 REGISTRATION STATEMENT
Capital/Financing Update
2023-11-13 English
FORM F-1 REGISTRATION STATEMENT
Capital/Financing Update
2023-11-13 English
FORM 6-K- New patent granted in China for pharmaceutical composition of NT219 expands IP protection
Regulatory Filings
2023-11-02 English
FORM 6-K- New patent granted in China for pharmaceutical composition of NT219 expands IP protection
Regulatory Filings
2023-11-02 English
FORM D Notice of Exempt Offering of Securities
Regulatory Filings
2023-10-31 English
FORM D Notice of Exempt Offering of Securities
Capital/Financing Update
2023-10-31 English
FORM F-1 - REGISTRATION STATEMENT
Regulatory Filings
2023-10-30 English
FORM F-1 - REGISTRATION STATEMENT
Regulatory Filings
2023-10-30 English
6K: Purple Biotech Announces Closing of $5Million Registered Direct Offering
Capital/Financing Update
2023-10-19 English
6K: Purple Biotech Announces Closing of $5Million Registered Direct Offering
Capital/Financing Update
2023-10-19 English
6K-SECURITIES PURCHASE AGREEMENT
Regulatory Filings
2023-10-19 English
6K-SECURITIES PURCHASE AGREEMENT
Capital/Financing Update
2023-10-19 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-10-19 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2023-10-19 English
6K:Purple Biotech Announces $5 Million Registered Direct Offering.
Capital/Financing Update
2023-10-17 English
6K:Purple Biotech Announces $5 Million Registered Direct Offering.
Report Publication Announcement
2023-10-17 English
Prospectus supplement to amend the Prior Prospectus to reduce capacity of the ATM
Capital/Financing Update
2023-10-17 English
Prospectus supplement to amend the Prior Prospectus to reduce capacity of the ATM
Report Publication Announcement
2023-10-17 English
6K-Company Presentation
Investor Presentation
2023-10-13 English
6K-Company Presentation
Report Publication Announcement
2023-10-13 English
6K-Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
Regulatory Filings
2023-10-07 English
6K-Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
Report Publication Announcement
2023-10-07 English
6K- Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Regulatory Filings
2023-10-03 English
6K- Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Report Publication Announcement
2023-10-03 English
6K- Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
Regulatory Filings
2023-09-21 English
6K- Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
Report Publication Announcement
2023-09-21 English
FORM 6-K- Company Presentation
Investor Presentation
2023-09-13 English
FORM 6-K- Company Presentation
Report Publication Announcement
2023-09-13 English
Second Quarter 2023 Financial Results
Earnings Release Q2 2023
2023-08-22 English
Second Quarter 2023 Financial Results
Report Publication Announcement
2023-08-22 English
Purple Biotech Reports PDAC Part A results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
Regulatory Filings
2023-07-11 English
Purple Biotech Reports PDAC Part A results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
Report Publication Announcement
2023-07-11 English
6K: Amendment No. 1- results of the Annual General Meeting of Shareholders of the Company held on June 15, 2023
Regulatory Filings
2023-06-20 English
6K: Amendment No. 1- results of the Annual General Meeting of Shareholders of the Company held on June 15, 2023
AGM Information
2023-06-20 English
Results of the Annual General Meeting of Shareholders of the Company held on June 15, 2023
AGM Information
2023-06-17 English
Results of the Annual General Meeting of Shareholders of the Company held on June 15, 2023
AGM Information
2023-06-17 English
The Tel Aviv District Court (Economic Division) dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed which was filed in December 2015
Regulatory Filings
2023-05-23 English
The Tel Aviv District Court (Economic Division) dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed which was filed in December 2015
Legal Proceedings Report
2023-05-23 English
Amendment No. 1 to Form F-3 Registration Statement
Capital/Financing Update
2023-05-17 English
Amendment No. 1 to Form F-3 Registration Statement
Report Publication Announcement
2023-05-17 English
First Quarter 2023 Financial Results and Provides Business Update
Interim / Quarterly Report Q1 2023
2023-05-16 English
First Quarter 2023 Financial Results and Provides Business Update
Report Publication Announcement
2023-05-16 English
Immediate Report of Meeting to be held on June 15, 2023,proxy
AGM Information
2023-05-01 English
Immediate Report of Meeting to be held on June 15, 2023,proxy
AGM Information
2023-05-01 English
Immediate Report of Meeting to be held on June 15, 2023,proxy
AGM Information
2023-05-01 English
Annual General Meeting of Shareholders to be held on June 15, 2023
AGM Information
2023-05-01 English
Annual General Meeting of Shareholders to be held on June 15, 2023
AGM Information
2023-05-01 English
6K:Purple Biotech Debuts Scientific Advisory Board
Regulatory Filings
2023-04-26 English
6K:Purple Biotech Debuts Scientific Advisory Board
Report Publication Announcement
2023-04-26 English
6K:Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
Regulatory Filings
2023-04-19 English
6K:Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
Report Publication Announcement
2023-04-19 English
6K:Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
Regulatory Filings
2023-03-25 English
6K:Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
Regulatory Filings
2023-03-25 English
FORM F-3 REGISTRATION STATEMENT
Capital/Financing Update
2023-03-23 English
FORM F-3 REGISTRATION STATEMENT
Capital/Financing Update
2023-03-23 English
6K:Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
Regulatory Filings
2023-03-16 English
6K:Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
Report Publication Announcement
2023-03-16 English
FORM 20F FOR 2022
Annual Report FY 2022
2023-03-04 English
FORM 20F FOR 2022
Report Publication Announcement
2023-03-04 English
First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
Regulatory Filings
2023-02-14 English
First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
Regulatory Filings
2023-02-14 English
6K- Fourth Quarter and Full-Year 2022 Financial Results
Earnings Release Q4 2022
2023-02-08 English
6K- Fourth Quarter and Full-Year 2022 Financial Results
Report Publication Announcement
2023-02-08 English
6K-Company Presentation
Investor Presentation
2023-02-04 English
6K-Company Presentation
Report Publication Announcement
2023-02-04 English
6K:Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
Regulatory Filings
2023-02-02 English
6K:Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
Regulatory Filings
2023-02-02 English
Purple Biotech Ltd. is announcing that it has made available an updated Company Presentation on its website.
Investor Presentation
2023-01-07 English
Purple Biotech Ltd. is announcing that it has made available an updated Company Presentation on its website.
Report Publication Announcement
2023-01-07 English
6K:Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
Regulatory Filings
2023-01-03 English
6K:Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
Report Publication Announcement
2023-01-03 English